#87c5f2

Logistics

Data Management

Desktop Operations

EPM Systems

Strategy and Planning

Project Management

Other Operations

#f9f9f9

Carla Stallings

Nicol Godfrey

Other

Supply Chain

Nilima Kutty-jones

Commercial Supply Chain

David Schisla

Sandy L.

Pharma Supply Chain

Patricia Magnafichi

Kristy Brady

Purvi Patel

John Kennedy

Eve Xie

Patrick Vonlanthen

Information Technology & Digital Transformation Transactions

Record and Information Management

Digital Transformation - Quality Engineering

Engineering

Quality Compliance

Quality Assurance

Technical

Development Analytics and Informatics

Commercial Data Management

IT Compliance

Data Solutions Architecture

IT Service Desk

Anwar Mahmood

Hazel Lai

Carly Nickerson

Pavan Verma

Sarah Chang

Evan Zhang

Mario Ramon

Nammie Doan Nguyen

Thao T. Tran

Business Systems Project

Network & Cloud

Information Security

ERP- SCM

Digital Transformation

Digital Transformation Head

Operations Quality Management

Area Operations

Steve Lubeck

Aviral Srivastava

Patricia A. Lufburrow

Anne-france Boyle

Mary Ellen Gonzalez

Ishwin Ghotra

Sai Vajha

Brad Graybehl

Production Planning

MSL Operations

Processes & Systems

Pharmaceutical Supply Chain and Manufacturing Technologies

Quantitative Analytics & Forecasting

Technical Operations

GMP QA

Substance Manufacturing

Enablement Technologies

Licensing and Contracts

Quality Engineering

Procurement

Antonio Menendez Rodriguez

R&D Strategic Outsourcing

Sunil Gali

David Harris

Andrew Auld-fisher

Sumit Debnath

Mickey Chatman

Andrew Bruevich

Sundeep Sharma Sathuluri

Calvin Yao

Kayla Dizon

Minako Usui

Dana Thompson

David Blackett

Veronica Jackson

Luis Bloise

Shelby Young

Operations

Risk Management and Business Operations

Clinical Operations

Facilites

CMC Development and Manufacturing

Raghu Achar

Franchise Strategy and Operations

Dodjie Arcayena

#1292ef

Exelixis

Marlon Tang

Matt Chung

Socrates Rajkumar Nachiappan

Exelixis is a genomics-based drug discovery company located in South San Francisco, Ca., and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. It works on the development of anti-cancer therapies. Exelixis has several compounds in various stages of FDA approval including :

XL147 that targets phosphoinositide-3 kinase (PI3K); and
XL765, which targets PI3K and mTOR, kinases in the PI3K signaling pathway.
XL880 (foretinib)


Pipeline
Overview
 
Pipeline
Overview
 
Unlocking Transformative Cancer Therapies
Our pipeline includes the Exelixis-discovered compounds, cabozantinib, cobimetinib and XL092, as well as other programs that are the subject of partnerships and collaborations with several biopharmaceutical companies. Safety and efficacy for these compounds in the unapproved uses or indications described below have not yet been established.
Pipeline Overview
Cabozantinib
Exelixis focuses its internal development efforts primarily upon cabozantinib, a targeted agent that inhibits the activity of receptor tyrosine kinases including MET, AXL, VEGF Receptors, and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment. Exelixis discovered cabozantinib internally and maintains exclusive rights to commercialize the product in the United States. Outside of the United States, Ipsen has exclusive commercialization and development rights for current and future cabozantinib indications, except in Japan, where Exelixis has granted exclusive rights to Takeda. Exelixis and its partners are collaborating on the global development plan for cabozantinib and Ipsen and Takeda are responsible for the development work supporting cabozantinib in their respective regions.
For information on approved uses of cabozantinib, please visit Our Medicines page.
Cobimetinib
Cobimetinib, an Exelixis-discovered compound, is a reversible inhibitor of MEK, part of the RAS/RAF/MEK/ERK pathway that is frequently dysregulated in human tumors. Cobimetinib is being developed by Genentech, a member of the Roche Group, under a collaboration agreement with Exelixis and is the subject of a broad clinical development program in combination with a variety of investigational and approved therapies.
Cobimetinib is now approved in multiple countries, including the United States, European Union, Switzerland, Canada, Australia and Brazil, to treat specific forms of BRAF mutation-positive unresectable or metastatic melanoma, in combination with vemurafenib. The trade name for cobimetinib is COTELLIC®. For more information on COTELLIC, including important safety information, please click here .
XL092
XL092 is a next-generation oral tyrosine kinase inhibitor that targets key signal transduction pathways in tumors, including VEGF receptors, MET, and other kinases implicated in cancer’s growth and spread. XL092 is the first new Exelixis-discovered compound to come out of the company’s reinitiated drug discovery activities; the compound entered phase 1 clinical development in 2019.
XL888
XL888 is a highly potent, orally bioavailable ATP-competitive inhibitor of HSP90, a molecular chaperone protein that affects the activity and stability of a range of key regulatory proteins, including kinases such as BRAF, MET, and VEGFR2. Exelixis discovered XL888 and owns the compound exclusively.
Cabozantinib Pipeline
Explore the diverse development program for our flagship molecul

Over the past two decades, Exelixis has gained substantial experience in the process of discovering, optimizing and developing candidate drugs to treat cancer.

Exelixis, Inc.